

PRESS RELEASE

St. Teresa Medical Announces Key Patent Issued

July 27, 2016 – St. Paul – St. Teresa Medical, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued Patent US 9,399,082 ELECTROSPUN DEXTRAN FIBERS AND DEVICES FORMED THEREFROM. This patent forms the key technology base for the St Teresa Medical platform technology called FASTCLOT® and its SURGICLOT® family of hemostasis products. SURGICLOT® uses the FASTCLOT® electrospun dextran matrix system to deliver human derived clotting proteins fibrinogen and thrombin to surgical, trauma and other injury sites to achieve hemostasis.

Philip Messina, President and CEO said, “We are very pleased to receive this patent. Our SURGICLOT® product, currently awaiting the CE Mark in Europe, is poised to become the treatment of choice for cancellous bone bleeding, once approved. Because our electrospun dextran delivery system dissolves when in contact with bodily fluids, SURGICLOT® actually shrinks in physical size as it works compared to competing hemostatic agents which swell. This is an especially crucial advantage in and around delicate tissues like the spine.”

FASTCLOT® is uniquely fabricated from nanoscale electro-spun dextran fibers infused with fibrinogen and thrombin and provides a robust and inexpensive platform for hemostatic products that are ideal for commercial use in surgical and trauma applications. FASTCLOT® is the only blood-clotting technology with a rapidly dissolvable delivery mechanism. FASTCLOT® works by supplementing and enhancing the body’s natural clotting mechanism. Dextran dissolves within seconds in contact with bodily fluids. Upon dissolving, the thrombin acts on the fibrinogen and converts it to fibrin which forms a natural clot at the injury site which stops bleeding.

SURGICLOT® utilizes thrombin and fibrinogen obtained from human sources.

St Teresa Medical has obtained the exclusive worldwide license for this patent from Virginia Commonwealth University and The Henry M. Jackson Foundation for the Advancement of Military Medicine.

The company now holds 3 patents in the US with 7 pending and 7 foreign patents with 22 pending.

About St. Teresa

St. Teresa Medical, Inc.®, based in St. Paul, Minn., is a medical-device company developing a new unique dissolvable hemostatic dressing called SURGICLOT®. For more information, see www.StTeresaMedical.com. For more information, contact Brian Jackson, CFO at 651-789-4633.

###